Altimmune, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ALT Nasdaq 2830 altimmune.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Altimmune, Inc.

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate - Dec 25th, 2024 11:26 am
Altimmune Added to Nasdaq Biotechnology Index - Dec 19th, 2024 12:30 pm
Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders - Dec 2nd, 2024 12:30 pm
Altimmune to Participate at Two Upcoming Investor Conferences - Nov 26th, 2024 12:30 pm
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 - Nov 15th, 2024 4:00 pm
Altimmune Third Quarter 2024 Earnings: Beats Expectations - Nov 14th, 2024 11:15 am
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update - Nov 12th, 2024 12:00 pm
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 11th, 2024 12:30 pm
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer - Nov 11th, 2024 12:30 pm
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity - Nov 7th, 2024 12:30 pm
Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 - Nov 4th, 2024 12:30 pm
Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024 - Oct 15th, 2024 12:00 pm
Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference - Oct 1st, 2024 11:30 am
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) - Sep 30th, 2024 11:30 am
CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes - Sep 10th, 2024 5:09 pm
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes - Sep 10th, 2024 11:45 am
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes - Sep 3rd, 2024 11:30 am
Altimmune First Half 2024 Earnings: Revenues Beat Expectations, EPS Lags - Aug 10th, 2024 1:03 pm
Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update - Aug 8th, 2024 11:00 am
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results - Aug 7th, 2024 11:00 am